Revolution pancreatic cancer drug nearly doubles survival in key trial

The subject of buyout rumors this year, Revolution posted Phase 3 results one analyst called a “game changer” in a tough-to-treat tumor. 

By Jonathan Gardner • April 13, 2026

FDA again spurns Replimune melanoma drug

In a statement late Friday, CEO Sushil Patel disputed the FDA’s criticisms of the company and said Replimune had received “inconsistent communications.” It’ll be forced to cut jobs as well.

By Ben Fidler • Updated April 13, 2026

Explore the Trendline➔

Cell therapy

The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases or in reprogramming cells inside the body.

By BioPharma Dive staff

Oricell closes a ‘pre-IPO’ megaround to aim CAR-T at solid tumors

The Shanghai-based biotech has a cell therapy that, if successful in testing, could become the first treatment of its kind for liver cancer. 

By Gwendolyn Wu • April 10, 2026

RFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degraders

The newly published charter widens the required expertise to become an ACIP member and stresses vaccine safety. Elsewhere, Gilead licensed a Kymera drug and a new RNA-focused startup emerged. 

By Ben Fidler • April 10, 2026

Women have awaited a revolution in menopause. It hasn’t arrived.

Persistent barriers are still hindering drug development for a host of menopause symptoms.

By Kelly Bilodeau • April 10, 2026

Invivyd reveals plans to test an antibody drug against measles

The drug, which Invivyd sees as a potential treatment and “targeted alternative” for the vaccine-hesitant, comes as measles cases in the U.S. are reaching levels not seen in decades. 

By Delilah Alvarado • April 9, 2026

Chasing a tough-to-treat lung disease, Avalyn plans an IPO

Backed by Novo Holdings and multiple other prominent investors, the biotech is developing what it’s positioning as superior versions of entrenched — but flawed — medicines for idiopathic pulmonary fibrosis.

By Gwendolyn Wu • April 9, 2026

Sidewinder secures $137M to advance ‘precision’ ADCs

Backed by OrbiMed, Novartis’ venture arm and many other investors, the biotech is among those working on newer technology that could broaden the reach of antibody-drug conjugates.

By Delilah Alvarado • April 8, 2026

Activist investor revives campaign to overhaul Novavax board

Shah Capital, which has agitated for change at the vaccine maker for years, is calling on fellow shareholders to end what it calls “dogmatic leadership” that’s led to the “destruction” of Novavax’s equity value. 

By Kristin Jensen • April 8, 2026

Jeito Capital, prominent biotech investor, raises $1.2B for next fund

Jeito claimed the new bankroll, which will support 15 to 20 clinical-stage companies, is the largest ever for a “fully independent European fund dedicated to biopharma.”

By Gwendolyn Wu • April 8, 2026

Novo underprices Lilly with higher-dose Wegovy; Insmed absorbs ‘expected’ study failure

Novo escalated a GLP-1 pricing war with the launch of its newest obesity medicine. Elsewhere, analysts came to Insmed’s defense and HHS changed the way panelists for a key vaccine committee are selected. 

By BioPharma Dive staff • April 8, 2026

Terns rebuffed a higher bid before selling to Merck

Regulatory filings show that Terns ultimately accepted an offer 15% lower than a previous proposal as four companies vied for rights to the coveted leukemia drug developer. 

By Jonathan Gardner • April 7, 2026

Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis

Gilead’s third acquisition since late February hands it a technology designed to make antibody-drug conjugates less toxic and multiple cancer medicines already in clinical testing.

By Gwendolyn Wu • April 7, 2026

FDA floats new clinical trial reforms; Takeda punts Denali brain drug

In its budget request, the agency proposed a way to speed up early drug testing and help smaller biotech firms. Elsewhere, two startups raised megarounds.

By BioPharma Dive staff • April 6, 2026

Neurocrine to acquire Prader-Will drug in $2.9B Soleno buyout

The deal hands Neurocrine a “controversial” medicine, Vykat, that achieved $190 million in sales last year but faces persistent questions about its growth trajectory and safety, according to Wall Street analysts. 

By Ben Fidler • April 6, 2026

Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM

Shares of Immunovant, Alto and Oric Pharmaceuticals fell this week on clinical trial updates. Elsewhere, Orca Bio’s cell therapy hit a delay and Korsana entered a reverse merger.

By BioPharma Dive staff • April 2, 2026

Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets

In an interview, Chief Financial Officer Robin Kramer said the combined cash flow from Biogen and Apellis will not only help debt leverage ratios but also free up capacity to do other strategic deals.

By Jacob Bell • April 1, 2026

Ambrosia adds a megaround for obesity drugs

The $100 million Series B round will be used to bring the biotech’s oral GLP-1 into early human testing.

By Gwendolyn Wu • Updated April 1, 2026

A ‘hijacked plane’: CDC, under RFK Jr.’s influence, trades science for dogma

A series of controversial policy changes directed by the HHS secretary have left experts fearful of the future implications for public health. 

By Delilah Alvarado , Shaun Lucas • April 1, 2026

FDA, after turbulent year, leaves drugmakers guessing on its direction

Constant leadership changes and erratic decision-making have left the biopharmaceutical industry feeling its chief regulator is as unpredictable as it’s ever been.

By Jonathan Gardner , Shaun Lucas • April 1, 2026

Lilly beefs up neuroscience pipeline with $6.3B Centessa buyout

The deal secures two sleep disorder drugs that would fill a hole in the company’s portfolio and intensify a competition with Takeda and Eisai.

By Jonathan Gardner • March 31, 2026

Viridian tumbles on positive data for key eye drug prospect

The data did not meet investor expectations, and could bring “fierce investor debate on commercial feasibility,” according to an analyst.

By Delilah Alvarado • March 31, 2026

Biogen, with $5.6B Apellis buy, builds out immunology offerings

Chief Financial Officer Robin Kramer explained how the deal not only provides two marketed products, but a team with nephrology expertise that will be valuable as Biogen prepares to launch felzartamab.

By Jacob Bell • March 31, 2026

Merck strikes deal with antibody discovery startup

In an R&D collaboration worth as much as $838 million, Merck will lean on Infinimmune to discover immune cell-directed antibodies for multiple targets.

By Gwendolyn Wu • March 31, 2026

mRNA is poised to rise beyond infectious diseases, if it’s not derailed by R&D cuts

Research into areas like cancer could become collateral damage of a broader anti-mRNA push, according to a new study.

By Alexandra Pecci • March 31, 2026